NCT03382977 2025-03-11
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
VBI Vaccines Inc.
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT02366663 2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3 Terminated
NCT00083551 2015-11-23
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
University of Arkansas
Phase 3 Completed
NCT00761280 2014-11-14
SAPPHIRE
Isarna Therapeutics GmbH
Phase 3 Terminated